|
|
|
|
| LEADER |
00000cgm a2200000Mi 4500 |
| 001 |
on1369591821 |
| 003 |
OCoLC |
| 005 |
20240909213021.0 |
| 006 |
m o c |
| 007 |
cr |n||||||||a |
| 007 |
vz |za|z| |
| 008 |
230125s2022 ne 017 e o vneng d |
| 040 |
|
|
|a ALSTP
|b eng
|e rda
|c ALSTP
|d CJT
|d OCLCF
|d OCLCO
|
| 019 |
|
|
|a 1373497146
|
| 020 |
|
|
|z 9789813366503
|
| 035 |
|
|
|a (OCoLC)1369591821
|z (OCoLC)1373497146
|
| 049 |
|
|
|a HCDD
|
| 245 |
0 |
0 |
|a Springer Nature medical video.
|p Intradetrusor botulinum toxin injection /
|c produced by Springer Nature.
|
| 246 |
3 |
0 |
|a Intradetrusor botulinum toxin injection
|
| 246 |
1 |
|
|i Sub-title on title screen :
|a Treatment of refractory overactive bladder
|
| 264 |
|
1 |
|a Dordrecht, South Holland :
|b Springer Nature,
|c 2022.
|
| 300 |
|
|
|a 1 online resource (17 minutes)
|
| 306 |
|
|
|a 001611
|
| 336 |
|
|
|a two-dimensional moving image
|b tdi
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 337 |
|
|
|a video
|b v
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a video file
|2 rdaft
|
| 490 |
0 |
|
|a Springer Nature Medical Video
|
| 500 |
|
|
|a Title from resource description page (viewed January 26, 2023).
|
| 520 |
|
|
|a Botulinum toxin-A is a potent neurotoxin produced by Clostridium botulinum that is an effective, minimally invasive treatment option for patients with pharmacologically refractory overactive bladder (OAB). OAB is a syndrome that is characterised by urgency and frequency with or without urgency urinary incontinence (UUI). Its prevalence among the global population approaches 11 % and the female to male ratio is approximately 3:2. OAB is associated with significant decrease in quality of life (QoL) in terms of health. Initial treatment for OAB includes conservative and oral pharmacological treatments. Onabotulinum toxin A (BoNT-A), is the only licensed formulation of botulinum toxin A, for idiopathic UUI at 100 units with the small risk of urinary retention (approximately 10%). Therefore patients should be able and willing to perform intermittent catheterization, before administration. In addition, the injections must be repeated on average every 6 to 9 months. This video gives a comprehensive overview of understanding the concept, evaluation and selection of patient, detailed operative technique with clear demonstration of tips to avoid potential complications and postoperative care. It will be helpful for all those specialists, who are dealing with Female Urology (Urogynecologists, female urologists, minimally invasive pelvic surgeons, reconstructive surgeons, general urologists, general gynecologists, medical students, residents, patients). It is included as the third line management for Urge urinary incontinence, in most of the recently published standard guidelines and is US Food and Drug Administration (FDA) approved.
|
| 546 |
|
|
|a In English.
|
| 650 |
|
0 |
|a Bladder
|x Diseases.
|
| 650 |
|
0 |
|a Urinary incontinence.
|
| 650 |
|
0 |
|a Botulinum toxin
|x Therapeutic use.
|
| 650 |
|
7 |
|a Bladder
|x Diseases
|2 fast
|
| 650 |
|
7 |
|a Botulinum toxin
|x Therapeutic use
|2 fast
|
| 650 |
|
7 |
|a Urinary incontinence
|2 fast
|
| 655 |
|
7 |
|a Educational films
|2 fast
|
| 655 |
|
7 |
|a Instructional films
|2 fast
|
| 655 |
|
7 |
|a Educational films.
|2 lcgft
|
| 655 |
|
7 |
|a Instructional films.
|2 lcgft
|
| 655 |
|
7 |
|a Films éducatifs.
|2 rvmgf
|
| 655 |
|
7 |
|a Films de formation.
|2 rvmgf
|
| 700 |
1 |
|
|a Jain, Amita,
|e on-screen presenter.
|
| 710 |
2 |
|
|a Springer Nature (Firm),
|e film distributor,
|e production company.
|
| 776 |
0 |
8 |
|i DVD version:
|z 9789813366503
|
| 856 |
4 |
0 |
|u https://holycross.idm.oclc.org/login?auth=cas&url=https://www.aspresolver.com/aspresolver.asp?MARC;5368724
|y Click for online access
|
| 903 |
|
|
|a ASP-AV
|
| 994 |
|
|
|a 92
|b HCD
|